InvestorsHub Logo
Followers 96
Posts 10079
Boards Moderated 0
Alias Born 06/11/2006

Re: RAND post# 440

Friday, 01/12/2018 9:36:41 AM

Friday, January 12, 2018 9:36:41 AM

Post# of 6217
4:42am est 1/12/18 Aviragen Therapeutics Board recommends that stockholders vote FOR the proposed merger with Vaxart
Briefing.com
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today reiterated its support of the pending merger with Vaxart, Inc., which was unanimously approved by the Aviragen Board of Directors. In reiterating its support for and recommending that Aviragen stockholders vote in favor of the proposed merger with Vaxart at the special meeting of stockholders on February 6, 2018, the Company notes that: The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart's estimated potential valuation prior to the merger is approximately $158 million. Aviragen stockholders will have the opportunity to participate in the significant upside potential of the mergerAviragen's Board conducted a thorough process that included an extensive review of strategic alternatives
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VXRT News